Kvh aktuell *pharma*kotherapie 1-2009: literaturliste

Dies ist eine PDF-Datei aus www.kvhessen.de.
Die Urheberrechte liegen bei derKassenärztlichen Vereinigung Hessen.
KVH aktuell Pharmakotherapie 1-2009: Literaturliste
Die Literaturliste zur Ausgabe Nr. 1-2009 von KVH aktuell Pharmakotherapie stellen wir Ihnen hier zur Verfügung Zu "Antipsychotika bei Demenz: Zulassungsbehörden erweitern wegen höherem Sterberisiko die Warnhinweise" von Dr. med. Joachim
Feßler, Klaus Hollmann
1 Alzheimer Forum Schweiz - Klinik und Forschung - Therapie, Therapie der Alzheimer-Krankheit2 Demenzkrankheit für Betroffene, Angehörige und Pflegende, Universität Witten-Herdecke3 GILL, S.S. et al.: Ann. Intern. Med. 20074 SCHNEEWEISS, S. et al.: CMAJ 20075 FDA Alert vom 16. Juni 2008: Information for Healthcare Professionals Zu "Protonenpumpenhemmer - Modedroge für jedes Magenproblem?" von Dr. med. Günter Hopf
1 Schwabe/Paffrath, Arzneiverordnungsreport 2008,S. 665 und S.6672 F.K.L.Chan, Proton-pump inhibitors in peptic ulcer disease, Lancet 2008; 372: 1198-12003 R.E.Aubert et al., Circulation 2008; 118: S 815 Zu "Gastroösophagealen Reflux mit Protonenpumpen-Inhibitoren behandeln oder laparoskopische Fundoplicatio anstreben? Neue Einblicke
und alte Weisheiten"
Ein Kommentar zu dem Artikel im British Medical Journal von Grant et al: "Minimal access surgery compared with medical management for
chronic gastro-oesophageal reflux disease: UK collaborative randomised trial, BMJ 2008; 337: 2664"
Von Dr. med. Margareta Frank-Doss
1 Klinkenberg-Knol et al. Long-term omeprazole treatment in resistent gastroesophageal reflux disease: Efficacy, safety, and influence on gastricmucosa. Gastro 2000; 118:6612 Gulmez et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch Intern Med2007; 167:9503 Aseeri et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients.
Am J Gastro 2008; 103 :23084 Marcuard et al. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Int Med 1994; 120:2115 Cundy et al. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69:3386 Targownik et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008; 179:2977 Pezalla et al. Initial assesment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:10388 Gilard et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with asipirin: the randomized, double-blind OCLA(Omeprazole Clopidogrel Aspirin) study. Am J Coll Cadiol 2008; 51:2569 Simpson et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 2006; 11:38110 Spechler SJ. The management of patients who have « failed » antireflux surgery. Am J Gastro 2004;157211 Mahon et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronicgastro-oesophageal reflux. Br J Surg 2005; 92:69512 Anvari et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronicgastrooesophageal reflux disease: one-year follow-up. Surg Innov 2006;13:238-24913 Freys SM, Fuchs KH. Endoskopische Antirefluxtherapie. Deutsches Ärzteblatt 2002; 99:85914 Lundell et al. Seven-year follow-up of a randomized clinical trail comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Brit JSurg 2007; 94:19815 Salminen et al. Comparison of long-term outcome of laparoscopic and conventional nissen fundoplication: a prospective randomized study with an11-year follow-up. Ann Surg 2007; 246:20116 Labenz et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol2006;101:2457 Zu "Die BEAUTIFUL-Studie zu Ivabradin - Herzfrequenz-Senker doch nicht so schön, wie der Pharmareferent erzählt?" von Dr. med. Jutta
Witzke-Gross
1 Fox K, Ford J, Steg G, Tendera M, Ferrari R, on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease
and left-ventrikular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet 2008; 372: 807-16
2 Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery
disease. Eur Heart J 2005; 26: 967-74
Zu "Wertigkeit der Therapie mit Sartanen" von Dr. med. Wolfgang LangHeinrich
1 Malaccco E et al: Blood Pressure Reduction on Tolerability of Valsartan in Comparison with Lisinopril Study (PREVAIL) - 2004. clin Ther 26:855-8652 Lüder S et al: The PHARAO Study: prevention of hypertension with the angiotensin-converting enzyme inhibitor Ramipril in Patients with high normalblood pressure. J Hypertens 26:1487-14963 Arzneiverordnungen in der Praxis: Therapieempfehlungen der Arzneimittelkommission der Deutschen Ärzteschaft. Arterielle Hypertonie 2. Auflage2004 4 Leitlinien für Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie der Deutschen Liga zur Bekämpfung des hohen Blutdrucks e.
V. AWMF Leitlinie5 The ONTARGET Investigators (2008): Telmisartan, Ramipril or both in Patients at high risk vor vascular events. N Engl J Med 358:1547-15596 Lancet 2008, 372:547-5537 Dahlöf B et al: The LIFE Study Group (2002): Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction inhypertension study (LIFE). Lancet 359:995-10038 Lithell H et al for the SCOPE Study Group (2003): The Study on Cognition and Prognosis in the Eldery (SCOPE). J Hypertens 21:875-8869 Pitt B et al: Effect of Losartan compared with Captopril on mortality in Patients with symptomatic heart failure randomised trail - the Losartan HeartFailure Servial Study ELITE II. Lancet 355:1582-158710 Dickstein K et al: Effects of Losartan an Captopril on mortality and morbidity in high risk Patients after myocardial infarction: the OPTIMALrandomised trail (2002). Lancet 360:752-76011 Therapie der Herzinsuffizienz - Empfehlungen der europäischen Gesellschaft für Kardiologie - Arzneimitteltherapie, WissenschaftlicheVerlagsgesellschaft Stuttgart 24 Jg Heft Januar 200612 Mc Murray et al: Effects of Candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-enzymeinhibitors: the CHARM-Added Trial (2003). Lancet 362:767-77113 Yusuf S et al (2003): Effect of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: theCHARM-Preserved Trial. Lancet 362:777-78114 Levy BI (2004): Can angiotensin II Typ 2 receptor have deleterious in cardiovasculair desease? Circulation 10 S: 8-1315 Barnett AH et al (2004): Angiotensin-reaptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med351:1952-196116 Yusuf S (2002): From the Hope to the ONTARGET and the TRANSCEND studies: challenges in improvising prognosis. AM J cardiol 89 (2A):18A-25A17 Abdulla J et al (2007): A systematic review: effect of angiotensin converting enzyme inhibitors on left ventricular volumes and ejection fraction inpatients with a myocardial infarction and in patients with left ventricular dysfunction Zu "Rationaler Einsatz von niedermolekularen Heparinen"
1 Schwabe U., Paffrath D., Arzneiverordnungsreport 2007, Seite 3912 Richard H. White1, Jeffrey S. Ginsberg2, Review; Low molecular weight heparins - are they all the same?; British Journal of Haematology, 2003; 121:12-203 Fachinformation Arixtra, Stand April 20074 Fachinformation Ogaran, Stand Dezember 20055 Arora N, Goldhaber SZ. Circulation 2006; 113: e698-e7026 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.
2004 Sep; 126(3 Suppl): 188S-203S7 Mosenkis A, Berns JS. Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease; Semin Dial.
2004 Sep-Oct; 17(5): 411-4158 Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin und weitere AWMF-Mitgliedsgesellschaften 2005. Diagnostik und Therapie derBein- und Beckenvenenthrombose und Lungenembolie.9 Monreal M, Falgá C, Valle R, Barba R, Bosco J, Beato JL, Maestre A; RIETE Investigators. Venous thromboembolism in patients with renalinsufficiency: findings from the RIETE Registry. Am J Med. 2006 Dec; 119 (12): 1073-107910 Verhave JC, Baljé-Volkers CP, Hillege HL, de Zeeuw D, de Jong PE. The reliability of different formulae to predict creatinine clearance. J InternMed. 2003 May; 253 (5): 56311 Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM: Influence of patientcharacteristics and renal functionon factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segement elevation acute coronarysyndromes. Am Heart J 143 (2002): 753-75912 Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V: Safety profile of tinzaparin administered once daily at a standard curative dose in two hundredvery elderly patients. Drug Safety 25, 2002; 725-3313 Sanderink GJ, Ozuox ML, Jariwala NU, Shukla UA, Boutouyrie. Pharmacokinetics and pharmacodynamics of the prophylatic dose of enoxaparinonce daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-23114 Schinzel H., Einsatz von niedermolekularen Heparinen bei Niereninsuffizienz, Vascular Care 1/2007 Vol.1215 Wuillemin WA, Wirz P, Welte S et al. Prophylaxe venöser Thromboembolien. Schweiz Med Forum 2007; 7: 198-20416 Geerts WH et al. Prevention of venous thromboembolism: The seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126: 338-40017 Encke A. Interdisziplinäre Leitlinie der Deutschen Gesellschaft für Chirurgie, Dt.Ges.f. Unfallchirurgie und anderer AWMF-Mitgliedsgesellschaften.
Stationäre und ambulante Thromboembolie-Prophylaxe in der Chirurgie und der perioperativen Medizin. Phlebologie 2003; 32: 164 ff.; FRAUENARZT44 (2003), 1013ff.18 Koscielny J et al. Notfall- und Hausarztmedizin 2007; 33: 194-19819 Kröger K. Dtsch Med Wochenschr 2005; 130: 1706-171020 Haas S., Niedermolekulare Heparine, Springer Medizin Verlag Heidelberg 2006; 14621 Bauersachs RM et al. 2007. Ärzteblatt, Heft 18, 4. Mai 2007; 1237-124422 Fachinformation Pradaxa, Stand März 2008

Source: http://www.kv-hessen.de/Wir_%C3%BCber_uns-p-2/Publikationen/KVH_aktuell_Pharmakotherapie_1_2009__Literaturliste-p-33948.pdf?highlight=pharma&char=A